Results 181 to 190 of about 47,556 (256)

Orthognathic Surgery Using 1-Desamino-8-D-Arginine Vasopressin (DDAVP) in a Patient With Von Willebrand Disease: A Case Report. [PDF]

Cureus
Usuda S, Kato S, Shiba H, Nakagawa T, Asoda S.   +4 more
europepmc   +1 more source

Proteolytic remodelling of the extracellular matrix by pericytes

The FEBS Journal, Volume 293, Issue 13, Page 3899-3953, July 2026.
Pericytes are specialised perivascular cells intimately connected with endothelial cells and essential for the maintenance of vascular beds. They contribute to the formation and remodelling of the extracellular matrix by actively secreting proteases and protease inhibitors.
Tina Burkhard, Ella Milne, Kate Qian, Paola Campagnolo, Salvatore Santamaria   +4 more
wiley   +1 more source

IL-8 and sCD40L predict platelet refractoriness and survival of pediatric patients with solid tumors receiving chemotherapy. [PDF]

BMC Cancer
Zhou C, Chen X, Xu J, Ma J, Lin J, Wang H.   +5 more
europepmc   +1 more source

The Swiss Haemophilia Registry–Report From the First 8 Years

Haemophilia, Volume 32, Issue 4, Page 923-932, July/August 2026.
ABSTRACT Introduction Patient registries capture disease related information and provide a valuable source for real‐world data on rare diseases and their management. The Swiss Haemophilia Registry (SHR) was established in 2015 on the basis of a new Swiss federal human research act.
Alessandra Bosch, Lorenzo Alberio, Pierre Fontana, Lukas Graf, Johanna A. Kremer Hovinga, Nicolas von der Weid, Mattia Rizzi, Manuela Albisetti, the Swiss Haemophilia Network   +8 more
wiley   +1 more source

Ruptured Anterior Communicating Artery Aneurysm Associated with von Willebrand Disease Treated Using the Woven EndoBridge Device: An Illustrated Case. [PDF]

J Neuroendovasc Ther
Koike Y, Shindo K, Endo H, Ogino T, Nakamura H.   +4 more
europepmc   +1 more source

Monitoring Extended Half‐Life Factor VIII and IX Concentrates: Performance in Routine Clotting‐and Thrombin Generation Assays

Haemophilia, Volume 32, Issue 4, Page 1002-1015, July/August 2026.
ABSTRACT Introduction Monitoring extended half‐life (EHL) factor (F) VIII and FIX products is complex, as discrepant results are obtained in different laboratory assays. Aim To provide an overview on assay accuracy based on a re‐assessment of previously published data as well as laboratory results of EHL spiking experiments for specific factor assays ...
An K. Stroobants, Eva‐Leonne Göttgens, Yvonne M. C. Henskens, Joop H. Jansen, Saskia E. M. Schols, Sanna R. Rijpma   +5 more
wiley   +1 more source

Increased impact of GPIb receptors on platelet adhesion under flow in severe COVID-19. [PDF]

Biophys Rep
Avtaeva Y, Guria K, Melnikov I, Kalinskaya A, Artemyeva G, Gabbasov Z.   +5 more
europepmc   +1 more source

Beyond Standard Half‐Life: Real‐world Pharmacokinetics of Efanesoctocog Alfa in a Single Centre

Haemophilia, Volume 32, Issue 4, Page 954-959, July/August 2026.
ABSTRACT Introduction Efanesoctocog alfa (EFA) is an ultra–extended half‐life factor VIII (FVIII) developed to address limitations of conventional prophylaxis in haemophilia A. Although the XTEND trials reported low interindividual pharmacokinetic (PK) variability, real‐world data remain important to better characterize PK profiles across patient ...
Laurent Sattler, Agathe Herb, Léa Pierre, Jordan Wimmer, Manon Dolt, Olivier Feugeas, Dominique Desprez   +6 more
wiley   +1 more source

Prophylaxis for von Willebrand disease: Is it time for parity with established practice in hemophilia A? [PDF]

Ther Adv Hematol
Sidonio RF, Corrales-Medina FF, Johnsen JM, Sholzberg M, Malcolmson C, Connell NT.   +5 more
europepmc   +1 more source

Endothelial activation and damage associated with steroid-refractory aGVHD are counteracted by ruxolitinib. [PDF]

Blood Adv
De Moner B, Martinez-Sanchez J, Escribano-Serrat S, Moreno-Castaño AB, Charry P, Cid J, Lozano M, Arellano-Rodrigo E, Salas MQ, Rovira M, Martínez C, Escolar G, Carreras E, Álvarez-Larrán A, Diaz-Ricart M.   +14 more
europepmc   +1 more source